Breaking Finance News

Abaxis Inc (NASDAQ:ABAX) has been upgraded to Hold in a report by Zacks Investment Research today.

Zacks Investment Research has upgraded Abaxis Inc (NASDAQ:ABAX) to Hold in a report released on 9/27/2016.

On 7/23/2015, Canaccord Genuity released a statement for Abaxis Inc (NASDAQ:ABAX) dropped the target price from $68.00 to $62.00. At the time, this indicated a possible upside of 0%.

Boasting a price of $50.62, Abaxis Inc (NASDAQ:ABAX) traded 0.12% higher on the day. The last stock price is up 7.53% from the two hundred day average, compared to the S&P 500 which has decreased -0.01% over the same period. The company has recorded a 50-day moving average of $49.79 and a 200-day moving average of $47.09. 52,767 shares of the stock traded hands, down from an avg. volume of 151,408

Recent Performance Chart

Abaxis Inc (NASDAQ:ABAX)

With a total market value of $0, Abaxis Inc has P/E ratio of 36.82 with a 52 week low of $37.71 and a 52 week high of $58.15 .

Also covering Abaxis Inc's price target, a total of 6 brokers have issued a research note on ABAX. The one year target is $53.42 with 2 analysts rating the company a strong buy, 0 brokerages rating the company a buy, 6 brokers rating the stock a hold, 1 firm rating the stock a underperform, and finally zero equity analysts rating the company a sell.

Brief Synopsis On Abaxis Inc (NASDAQ:ABAX)

Abaxis, Inc. is a developer, manufacturer and marketer of portable blood analysis systems that are used in medical specialties in human or veterinary patient care to provide clinicians with blood constituent measurements. The Company markets and sells its products around the world through independent distributors and direct sales force. The Company's segments are the medical market and the veterinary market. The Company's medical market products include Piccolo chemistry analyzers and consumable products. The Company develops, manufactures and sells the Piccolo Xpress chemistry analyzer for use in human patient care to provide clinicians with blood constituent measurements. The Company's veterinary market product offerings include VetScan chemistry analyzers and veterinary reagent discs, VetScan hematology instruments and related reagent kits, VetScan VSpro specialty analyzers and related consumables, VetScan i-STAT analyzers and related consumables and VetScan rapid tests.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *